Moberg Pharma Ab · OMXSTO:MOB
Moberg Pharma Ab — Redeye Investor Forum, Stockholm 2026
17 slides from Moberg Pharma Ab's conference presentation, Sep 23, 2026
Slide 1: A novel topical treatment for onychomycosis – introducing Terclara
A novel topical treatment for onychomycosis – introducing Terclara® September 23, 2026 Redeye Investor Forum, Stockholm Anna Ljung, CEO
Slide 2: Disclaimer
Disclaimer The purpose of this presentation (the "Presentation") is to provide an overview of Moberg Pharma AB (publ) (the "Company"). For the purposes of this notice, "Presentation" means this document, its contents or any part of it, any oral presentation, any question or answer session and any wr
Slide 3: Potential new global market leader in Onychomycosis
Potential new global market leader in Onychomycosis Terclara® is a new topical Market approvals Very successful launch in treatment for nail fungus in place in 14 countries Scandinavia, European based on terbinafine rollout ongoing
Slide 4: Oral terbinafine is the gold standard for treatment of toenail fungus
Oral terbinafine is the gold standard for treatment of toenail fungus x40 Terclara® delivers terbinafine terbinafine in nailbed directly and effectively to the nail with Terclara® vs levels seen with oral treatment* x1,000 76% less terbinafine with Terclara® (MOB-015) in mycological cure* plasma vs
Slide 5: Why does Terclara win with patients?
Why does Terclara® win with patients? ▸ Kills the fungus ▸ It is safe ▸ Easy to apply ▸ Quick visible improvement * Mantap marketing survey, 2023
Slide 6: Strong premium position from true advantage
Strong premium position from true advantage Terclara´s mycological cure rate OTC Terabinafin allows for a price premium Mycological cure 76% OTC Amorolfin Mycological cure Mycological cure approx. 20%* Products based on devices Unclear to low cure Cosmetic Medical
Slide 7: 70+ million patients in Europe need better treatment for nail fungus
70+ million patients in Europe need better treatment for nail fungus 10% of the population suffer 7/10 doctors avoid prescribing from nail fungus1 terbinafine tablets2 USD 2bn global onychomycosis market.3 1) PLoS Pathog. 2014 Jun; 10(6): e1004105. 2) due to patients´ concerns for serious side effec
Slide 8: Strong drivers behind underlying market growth
Strong drivers behind underlying market growth 1. High prevalence 2. Aging population 3. Lifestyle factors 4. Growing aesthetic concerns 5. Rising awareness and willingness to treat * Grand View Research, Mordorin Intelligence, GMI, Research & Markets
Slide 9: Terclara expands the market
Terclara® expands the market Terclara’s strong proposition for consumers unlocks the 100% prevalence market growth potential = 100% usage Conversion of non- treaters 44% do not Growth potential treat Conversion Market of “mal- potential treaters” Users of Increased deferior frequency products Satisf
Slide 10: Terclara continues to improve its market leading position in Sweden
Terclara® continues to improve its market leading position in Sweden 44% Terclara® 37% Terclara® volume Terclara® has become the value share share clear market leader and no. of units driven category growth – in a highly competitive market * IQVIA MIDAS, Pharmacy Sell-Out data, rolling 12 months, Ju
Slide 11: Awarded 'Launch of the year' 2024 by major Swedish pharmacies
Awarded ’Launch of the year’ 2024 by major Swedish pharmacies DOZ pharmacy chain: 'A world class launch that has revitalized the category. The product has quickly become a market leader, driving progress forward and helping us gain market share. With the support of educational materials, we have tog
Slide 12: Terclara maintains its market leading position in Norway
Terclara® maintains its market leading position in Norway as second launch year progresses Terclara® launch 36% Terclara® 32% Terclara® volume value share share nominated for “Launch of no. of units the Year 2025” by the pharmacy chains Apotek 1 and Alliance Healthcare * IQVIA MIDAS, Pharmacy Sell-I
Slide 13: Strong commercial partners in place
Strong commercial partners in place • Partners in place for Europe, Canada, APAC, China, Scandinavia, Israel • Latest addition: Karo Healthcare, a capable partner with global reach – Lamisil®: The leading global brand for onychomycosis – Established distribution across all major pharmacies – Proven
Slide 14: Terclara is approved in 13 European countries
Terclara® is approved in 13 European countries Market approvals • Austria - OTC • France - Rx • Norway - OTC • Belgium - OTC • Hungary - OTC • Spain - Rx • Czech Rep. - Rx • Ireland - Rx • Sweden - OTC • Denmark - Rx • Italy - OTC • Finland - Rx • Netherlands - OTC Pipeline of additional approvals f
Slide 15: Moberg Pharma, a pharma company with a strong track record
Behind Terclara: Moberg Pharma, a pharma company with a strong track record • Moberg Pharma’s R&D is based on discoveries of late Dr. Sven Moberg of Sahlgrenska University Hospital in Gothenburg, Sweden. • All Moberg Pharma products contains a patented keratolytic carrier which also promotes the vis
Slide 16: Executive summary
Executive summary ► Unprecedented ability to ► Terclara® became the market leader in kill dermatophytes: 76% of patients Sweden and Norway instantly after became fungus free, in two phase 3- starting consumer marketing studies (800+ patients) ► Partners in place for Europe, Canada, ► Terbinafine, th
Slide 17: Anna Ljung, CEO
Anna Ljung, CEO +46 707 66 60 30, anna.ljung@mobergpharma.se
Moberg Pharma — Redeye Investor Forum, Stockholm 2026 on 6ix